PT1297851E - Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca - Google Patents
Inibicao de histona-desacetilase como tratamento para hipertrofia cardiacaInfo
- Publication number
- PT1297851E PT1297851E PT02021676T PT02021676T PT1297851E PT 1297851 E PT1297851 E PT 1297851E PT 02021676 T PT02021676 T PT 02021676T PT 02021676 T PT02021676 T PT 02021676T PT 1297851 E PT1297851 E PT 1297851E
- Authority
- PT
- Portugal
- Prior art keywords
- cardiac hypertrophy
- desacetilase
- histone
- inhibition
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32531101P | 2001-09-27 | 2001-09-27 | |
US33404101P | 2001-10-31 | 2001-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1297851E true PT1297851E (pt) | 2005-06-30 |
Family
ID=26984878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT02021676T PT1297851E (pt) | 2001-09-27 | 2002-09-27 | Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca |
Country Status (8)
Country | Link |
---|---|
US (4) | US6706686B2 (pt) |
EP (1) | EP1297851B1 (pt) |
JP (2) | JP2003238445A (pt) |
AT (1) | ATE287731T1 (pt) |
DE (1) | DE60202727T2 (pt) |
DK (1) | DK1297851T3 (pt) |
ES (1) | ES2236415T3 (pt) |
PT (1) | PT1297851E (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1476500A (en) * | 1998-11-10 | 2000-05-29 | Board Of Regents, The University Of Texas System | Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
JP2001149081A (ja) * | 1999-11-29 | 2001-06-05 | Cyclex Co Ltd | 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法 |
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20040077083A1 (en) * | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070104688A1 (en) * | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
US20040171118A1 (en) * | 2003-02-13 | 2004-09-02 | City Of Hope | Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs |
US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
MXPA05012619A (es) * | 2003-05-21 | 2006-02-08 | Univ Texas | Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. |
US20070190022A1 (en) * | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
EP1715870A1 (en) * | 2004-02-02 | 2006-11-02 | Myogen, Inc. | Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure |
US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
CA2561954A1 (en) * | 2004-04-05 | 2005-10-20 | Myogen, Inc. | Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
ES2701704T3 (es) | 2004-04-07 | 2019-02-25 | Ncardia Ag | Sistemas de ensayo tisulares funcionales no invasivos in vitro |
WO2005108598A1 (en) | 2004-05-11 | 2005-11-17 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
FI20040675A0 (fi) * | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä sydämen hypertrofian hoitoon ja estoon |
US20060110390A1 (en) * | 2004-08-25 | 2006-05-25 | Myogen, Inc. | Inhibition of Ku as a treatment for cardiovascular diseases |
WO2006060382A2 (en) * | 2004-11-30 | 2006-06-08 | Trustees Of The University Of Pennsylvania | Use of hdac and/or dnmt inhibitors for treatment of ischemic injury |
WO2006066133A2 (en) * | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7772245B2 (en) | 2005-02-14 | 2010-08-10 | Miikana Therapeutics, Inc. | Inhibitors of histone deacetylase |
US7604939B2 (en) * | 2005-03-01 | 2009-10-20 | The Regents Of The University Of Michigan | Methods of identifying active BRM expression-promoting HDAC inhibitors |
US20100087328A1 (en) * | 2005-03-01 | 2010-04-08 | The Regents Of The University Of Michigan | Brm expression and related diagnostics |
WO2006122319A2 (en) * | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
ZA200800901B (en) * | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
EP1901764A1 (en) * | 2005-07-14 | 2008-03-26 | Myogen, Inc. | Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
MX2008001964A (es) * | 2005-08-10 | 2008-03-26 | Novartis Ag | Metodo de uso de inhibidores de desacetilasa. |
WO2007059533A2 (en) * | 2005-11-18 | 2007-05-24 | Myogen, Inc. | Uses for camki i and hdacs in the treatment of heart conditions |
WO2007061939A2 (en) * | 2005-11-18 | 2007-05-31 | Gloucester Pharmaceuticals, Inc. | Metabolite derivatives of the hdac inhibitor fk228 |
US20070207950A1 (en) * | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
EP1976835A2 (en) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
CA2647359A1 (en) * | 2006-03-29 | 2007-11-08 | Edward Via Virginia College Of Osteopathic Medicine | Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites |
EP2004234A2 (en) * | 2006-04-06 | 2008-12-24 | Novartis AG | Combination of organic compounds |
AU2007238600B2 (en) | 2006-04-13 | 2012-01-19 | Wake Forest University Health Sciences | C-nitroso-derived nitroxyl donors |
WO2007145704A2 (en) * | 2006-04-24 | 2007-12-21 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
WO2007146730A2 (en) * | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
AU2007342028B2 (en) * | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
CN101687010A (zh) * | 2006-12-29 | 2010-03-31 | 格洛斯特制药公司 | 制备Romidepsin |
WO2008140708A1 (en) * | 2007-05-09 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Use of hdac inhibitors for treatment of cardiac rhythm disorders |
US7737175B2 (en) * | 2007-06-01 | 2010-06-15 | Duke University | Methods and compositions for regulating HDAC4 activity |
US9226965B2 (en) * | 2007-10-05 | 2016-01-05 | U.S. Department Of Veterans Affairs | Method and composition for treating heart failure |
WO2009089598A2 (en) * | 2008-01-18 | 2009-07-23 | Katholieke Universiteit Leuven | Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer |
WO2010039697A2 (en) * | 2008-09-30 | 2010-04-08 | Gilead Sciences, Inc. | Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy |
US9512481B2 (en) | 2009-09-11 | 2016-12-06 | The Regents Of The University Of Colorado, A Body Corporate | Polymorphisms in the PDE3A gene |
MY185130A (en) | 2010-07-12 | 2021-04-30 | Celgene Corp | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
EP2627316B1 (en) | 2010-10-13 | 2019-03-27 | Medivir AB | Pharmaceutical formulation for histone deacetylase inhibitors |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
IL294052A (en) | 2019-12-20 | 2022-08-01 | Tenaya Therapeutics Inc | Fluoroalkyl-oxadiazoles and their uses |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5968981A (en) * | 1995-07-28 | 1999-10-19 | The Regents Of The University Of California | Retinoid suppression of ventricular muscle cell hypertrophy |
JP2002528391A (ja) | 1998-10-19 | 2002-09-03 | メチルジェン,インク. | 組合せ治療による遺伝子発現の修飾 |
JP4269041B2 (ja) | 1999-03-02 | 2009-05-27 | 国立大学法人九州工業大学 | 新規な環状テトラペプチド誘導体とその医薬用途 |
JP2003500052A (ja) | 1999-05-03 | 2003-01-07 | メチルジーン インコーポレイテッド | ヒストン脱アセチル酵素の抑制 |
AU6794700A (en) | 1999-08-20 | 2001-03-19 | Board Of Regents, The University Of Texas System | Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression |
JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
WO2001017514A1 (en) * | 1999-09-03 | 2001-03-15 | The Salk Institute For Biological Studies | Modulation of gene expression by modulating histone acetylation |
JP2003508501A (ja) | 1999-09-07 | 2003-03-04 | コンジュケム,インコーポレーテッド | 生物学的結合のための肺送達 |
WO2001018045A1 (en) | 1999-09-08 | 2001-03-15 | Sloan-Kettering Institute For Cancer Research | Crystal structure of a deacetylase and inhibitors thereof |
CA2391952C (en) | 1999-11-23 | 2012-01-31 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2393725A1 (en) | 1999-12-08 | 2001-06-14 | Axys Pharmaceuticals, Inc. | Histone deacetylase-8 proteins, nucleic acids, and methods of use |
JP2003528074A (ja) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
CA2408385A1 (en) | 2000-03-24 | 2001-09-24 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
JP2001348340A (ja) | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
EP1170008A1 (en) | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
NZ525439A (en) | 2000-09-29 | 2004-11-26 | Topotarget Uk Ltd | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US20040077046A1 (en) | 2000-12-20 | 2004-04-22 | Dalia Cohen | Histone deacetylase-related gene and protein |
AR035513A1 (es) | 2000-12-23 | 2004-06-02 | Hoffmann La Roche | Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos |
US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
-
2002
- 2002-09-26 US US10/256,221 patent/US6706686B2/en not_active Expired - Fee Related
- 2002-09-27 ES ES02021676T patent/ES2236415T3/es not_active Expired - Lifetime
- 2002-09-27 PT PT02021676T patent/PT1297851E/pt unknown
- 2002-09-27 JP JP2002284313A patent/JP2003238445A/ja not_active Withdrawn
- 2002-09-27 AT AT02021676T patent/ATE287731T1/de not_active IP Right Cessation
- 2002-09-27 DE DE60202727T patent/DE60202727T2/de not_active Expired - Lifetime
- 2002-09-27 EP EP02021676A patent/EP1297851B1/en not_active Expired - Lifetime
- 2002-09-27 DK DK02021676T patent/DK1297851T3/da active
-
2004
- 2004-03-16 US US10/801,985 patent/US6946441B2/en not_active Expired - Fee Related
-
2005
- 2005-07-26 US US11/190,074 patent/US20060025333A1/en not_active Abandoned
- 2005-08-30 US US11/215,844 patent/US20060069014A1/en not_active Abandoned
-
2009
- 2009-09-25 JP JP2009221681A patent/JP2010001311A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1297851B1 (en) | 2005-01-26 |
US20060025333A1 (en) | 2006-02-02 |
DE60202727T2 (de) | 2005-12-29 |
DE60202727D1 (de) | 2005-03-03 |
US6946441B2 (en) | 2005-09-20 |
JP2003238445A (ja) | 2003-08-27 |
DK1297851T3 (da) | 2005-05-30 |
ATE287731T1 (de) | 2005-02-15 |
US20040186049A1 (en) | 2004-09-23 |
EP1297851A1 (en) | 2003-04-02 |
US20060069014A1 (en) | 2006-03-30 |
US6706686B2 (en) | 2004-03-16 |
ES2236415T3 (es) | 2005-07-16 |
JP2010001311A (ja) | 2010-01-07 |
US20030144340A1 (en) | 2003-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1297851E (pt) | Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca | |
DE60222302D1 (de) | Inhibitoren von mitotischem kinesin | |
ATE356804T1 (de) | Inhibitoren von mitotischem kinesin | |
ATE447577T1 (de) | Mitotische kinesin-hemmer | |
ATE448207T1 (de) | Mitotische kinesin-hemmer | |
ATE446094T1 (de) | Mitotische kinesin-hemmer | |
ATE421512T1 (de) | Inhibitoren von mitotischem kinesin | |
UY27224A1 (es) | Inhibidores de la rho-quinasa | |
EP1551812A4 (en) | MITOTIC KINESINE HEMMER | |
DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
DE60318177D1 (de) | Rho-kinase inhibitoren | |
SG151303A1 (en) | New compounds for the inhibition of angiogenesis and use thereof | |
EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
WO2003099211A3 (en) | Mitotic kinesin inhibitors | |
EA201100874A1 (ru) | Соединения для лечения рака | |
DK1648484T3 (da) | Fremgangsmåde til behandling af arthritis-tilstande | |
WO2005065183A3 (en) | Mitotic kinesin inhibitors | |
NO20076186L (no) | Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav | |
MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
DE60328603D1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren | |
BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
EA202190902A1 (ru) | Ингибирование синтазы жирных кислот (fasn) | |
DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen |